Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSN084 in Advanced Malignant Tumors
NCT06386705Phase 1Recruiting
- Sponsor
- Tyligand Bioscience
- Start
- Jul 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TSN084 in advanced malignant solid tumor (2 arms), sponsored by Tyligand Bioscience. Primary endpoints: Dose Limiting Toxicity at 28 days and Treatment-Emergent Adverse Events at 3 years. Started Jul 2022; status: recruiting.
02
Drugs
TSN084
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT06386705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06386705.